Apogee Therapeutics, Inc.
apogeetherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed Aug 10, 2026. Its latest SEC filing is a 15-12G from Sep 14, 2026.
10-Q for Q2 FY2026, filed Aug 10, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops antibody drug candidates for inflammatory and immune diseases, including atopic dermatitis, asthma and eosinophilic esophagitis, for patients.
10-K for FY2025, filed Mar 2, 2026
How Did They Make Money?
No revenue was reported.
10-K for FY2025, filed Mar 2, 2026
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$85.9MView ↗
- ▲ +30% (Loss)
- vs −$66.1M in Q2 FY2025
-
Sep 3, 2026
AbbVie completed its acquisition of Apogee
Apogee became an indirect wholly owned subsidiary of AbbVie.
Sources
8-K, filed Sep 3, 2026
As a result of the consummation of the Merger, there was a change in control of the Company, and the Company became an indirect wholly…View ↗
Loading...
